{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T20:25:00Z","timestamp":1768681500436,"version":"3.49.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2-3","license":[{"start":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T00:00:00Z","timestamp":1617408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T00:00:00Z","timestamp":1617408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000038"],"award-info":[{"award-number":["82000038"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Microbiol Immunol"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The current outbreak of coronavirus disease 2019 (COVID-19) has affected people around the world. Typically, COVID-19 originates in the lung, but lately it can extend to other organs and lead to tissue injury and multiorgan failure in severe patients, such as acute respiratory distress syndrome (ARDS), kidney failure and sepsis or systemic inflammation. Given that COVID-19 has been detected in a range of other organs, the COVID-19-associated disease is an alert of aberrant activation of host immune response which drives un-controlled inflammation that affects multiple organs. Complement is a vital component of innate immunity where it forms the first line of defense against potentially harmful microbes, but its role in COVID-19 is still not clear. Notably, the abnormal activation and continuous deposits of complement components were identified in the pre-clinical samples from COVID-19 patients, which have been confirmed in animal models. Recent evidence has revealed that the administration of complement inhibitors leads to relieve inflammatory response in ARDS. Hence, we speculate that the targeting complement system could be a potential treatment option for organ damage in COVID-19 patients.<\/jats:p>","DOI":"10.1007\/s00430-021-00704-7","type":"journal-article","created":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T07:02:52Z","timestamp":1617433372000},"page":"101-109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["An update: the emerging evidence of complement involvement in COVID-19"],"prefix":"10.1007","volume":"210","author":[{"given":"Qin","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4719-7464","authenticated-orcid":false,"given":"Zi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,3]]},"reference":[{"issue":"8","key":"704_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus I, Research T (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382(8):727\u2013733. https:\/\/doi.org\/10.1056\/NEJMoa2001017","journal-title":"N Engl J Med"},{"issue":"24","key":"704_CR2","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1056\/NEJMc2010419","volume":"382","author":"P Goyal","year":"2020","unstructured":"Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, Satlin MJ, Campion TR Jr, Nahid M, Ringel JB, Hoffman KL, Alshak MN, Li HA, Wehmeyer GT, Rajan M, Reshetnyak E, Hupert N, Horn EM, Martinez FJ, Gulick RM, Safford MM (2020) Clinical characteristics of Covid-19 in New York City. N Engl J Med 382(24):2372\u20132374. https:\/\/doi.org\/10.1056\/NEJMc2010419","journal-title":"N Engl J Med"},{"issue":"16","key":"704_CR3","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1001\/jama.2020.5394","volume":"323","author":"G Grasselli","year":"2020","unstructured":"Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, Iotti G, Latronico N, Lorini L, Merler S, Natalini G, Piatti A, Ranieri MV, Scandroglio AM, Storti E, Cecconi M, Pesenti A, Network C-LI (2020) Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 323(16):1574\u20131581. https:\/\/doi.org\/10.1001\/jama.2020.5394","journal-title":"JAMA"},{"key":"704_CR4","doi-asserted-by":"publisher","first-page":"104357","DOI":"10.1016\/j.jcv.2020.104357","volume":"127","author":"JA Siordia Jr","year":"2020","unstructured":"Siordia JA Jr (2020) Epidemiology and clinical features of COVID-19: a review of current literature. J Clin Virol 127:104357. https:\/\/doi.org\/10.1016\/j.jcv.2020.104357","journal-title":"J Clin Virol"},{"issue":"4","key":"704_CR5","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","volume":"5","author":"Coronaviridae Study Group of the International Committee on Taxonomy of V","year":"2020","unstructured":"Coronaviridae Study Group of the International Committee on Taxonomy of V (2020) The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 5(4):536\u2013544. https:\/\/doi.org\/10.1038\/s41564-020-0695-z","journal-title":"Nat Microbiol"},{"issue":"19","key":"704_CR6","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","volume":"367","author":"AM Zaki","year":"2012","unstructured":"Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367(19):1814\u20131820. https:\/\/doi.org\/10.1056\/NEJMoa1211721","journal-title":"N Engl J Med"},{"issue":"10","key":"704_CR7","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1056\/NEJMc2001468","volume":"382","author":"C Rothe","year":"2020","unstructured":"Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, Zimmer T, Thiel V, Janke C, Guggemos W, Seilmaier M, Drosten C, Vollmar P, Zwirglmaier K, Zange S, Wolfel R, Hoelscher M (2020) Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med 382(10):970\u2013971. https:\/\/doi.org\/10.1056\/NEJMc2001468","journal-title":"N Engl J Med"},{"issue":"14","key":"704_CR8","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1001\/jama.2020.2565","volume":"323","author":"Y Bai","year":"2020","unstructured":"Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, Wang M (2020) Presumed asymptomatic carrier transmission of COVID-19. JAMA 323(14):1406\u20131407. https:\/\/doi.org\/10.1001\/jama.2020.2565","journal-title":"JAMA"},{"issue":"1","key":"704_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00441-010-1034-0","volume":"343","author":"JV Sarma","year":"2011","unstructured":"Sarma JV, Ward PA (2011) The complement system. Cell Tissue Res 343(1):227\u2013235. https:\/\/doi.org\/10.1007\/s00441-010-1034-0","journal-title":"Cell Tissue Res"},{"issue":"2","key":"704_CR10","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.4049\/jimmunol.166.2.1193","volume":"166","author":"M Huber-Lang","year":"2001","unstructured":"Huber-Lang M, Sarma VJ, Lu KT, McGuire SR, Padgaonkar VA, Guo RF, Younkin EM, Kunkel RG, Ding J, Erickson R, Curnutte JT, Ward PA (2001) Role of C5a in multiorgan failure during sepsis. J Immunol 166(2):1193\u20131199. https:\/\/doi.org\/10.4049\/jimmunol.166.2.1193","journal-title":"J Immunol"},{"issue":"6","key":"704_CR11","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/bjh.15062","volume":"180","author":"CB Keragala","year":"2018","unstructured":"Keragala CB, Draxler DF, McQuilten ZK, Medcalf RL (2018) Haemostasis and innate immunity\u2014a complementary relationship: a review of the intricate relationship between coagulation and complement pathways. Br J Haematol 180(6):782\u2013798. https:\/\/doi.org\/10.1111\/bjh.15062","journal-title":"Br J Haematol"},{"issue":"2","key":"704_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s41030-020-00118-5","volume":"6","author":"N Maglakelidze","year":"2020","unstructured":"Maglakelidze N, Manto KM, Craig TJ (2020) A review: does complement or the contact system have a role in protection or pathogenesis of COVID-19? Pulm Ther 6(2):169\u2013176. https:\/\/doi.org\/10.1007\/s41030-020-00118-5","journal-title":"Pulm Ther"},{"issue":"1","key":"704_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cell.2020.05.032","volume":"182","author":"B Shen","year":"2020","unstructured":"Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C, Quan S, Zhang F, Sun R, Qian L, Ge W, Liu W, Liang S, Chen H, Zhang Y, Li J, Xu J, He Z, Chen B, Wang J, Yan H, Zheng Y, Wang D, Zhu J, Kong Z, Kang Z, Liang X, Ding X, Ruan G, Xiang N, Cai X, Gao H, Li L, Li S, Xiao Q, Lu T, Zhu Y, Liu H, Chen H, Guo T (2020) Proteomic and metabolomic characterization of COVID-19 patient sera. Cell 182(1):59\u201372. https:\/\/doi.org\/10.1016\/j.cell.2020.05.032","journal-title":"Cell"},{"issue":"1","key":"704_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cels.2020.05.012","volume":"11","author":"CB Messner","year":"2020","unstructured":"Messner CB, Demichev V, Wendisch D, Michalick L, White M, Freiwald A, Textoris-Taube K, Vernardis SI, Egger AS, Kreidl M, Ludwig D, Kilian C, Agostini F, Zelezniak A, Thibeault C, Pfeiffer M, Hippenstiel S, Hocke A, von Kalle C, Campbell A, Hayward C, Porteous DJ, Marioni RE, Langenberg C, Lilley KS, Kuebler WM, Mulleder M, Drosten C, Suttorp N, Witzenrath M, Kurth F, Sander LE, Ralser M (2020) Ultra-high-throughput clinical proteomics reveals classifiers of COVID-19 infection. Cell Syst 11(1):11\u201324. https:\/\/doi.org\/10.1016\/j.cels.2020.05.012","journal-title":"Cell Syst"},{"issue":"1","key":"704_CR15","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/22221751.2020.1747363","volume":"9","author":"Y Xiong","year":"2020","unstructured":"Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A, Guo D, Hu W, Yang J, Tang Z, Wu H, Lin Y, Zhang M, Zhang Q, Shi M, Liu Y, Zhou Y, Lan K, Chen Y (2020) Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect 9(1):761\u2013770. https:\/\/doi.org\/10.1080\/22221751.2020.1747363","journal-title":"Emerg Microbes Infect"},{"issue":"6","key":"704_CR16","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1182\/blood.2020006695","volume":"136","author":"A Berzuini","year":"2020","unstructured":"Berzuini A, Bianco C, Paccapelo C, Bertolini F, Gregato G, Cattaneo A, Erba E, Bandera A, Gori A, Lamorte G, Manunta M, Porretti L, Revelli N, Truglio F, Grasselli G, Zanella A, Villa S, Valenti L, Prati D (2020) Red cell-bound antibodies and transfusion requirements in hospitalized patients with COVID-19. Blood 136(6):766\u2013768. https:\/\/doi.org\/10.1182\/blood.2020006695","journal-title":"Blood"},{"issue":"6","key":"704_CR17","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1182\/blood.2020007483","volume":"136","author":"JE Hendrickson","year":"2020","unstructured":"Hendrickson JE, Tormey CA (2020) COVID-19 and the Coombs test. Blood 136(6):655\u2013656. https:\/\/doi.org\/10.1182\/blood.2020007483","journal-title":"Blood"},{"issue":"2","key":"704_CR18","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.virol.2010.12.045","volume":"411","author":"KA Stoermer","year":"2011","unstructured":"Stoermer KA, Morrison TE (2011) Complement and viral pathogenesis. Virology 411(2):362\u2013373. https:\/\/doi.org\/10.1016\/j.virol.2010.12.045","journal-title":"Virology"},{"key":"704_CR19","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.20.20104398","author":"LM Lam","year":"2020","unstructured":"Lam LM, Murphy SJ, Kuri-Cervantes L, Weisman AR, Ittner CAG, Reilly JP, Pampena MB, Betts MR, Wherry EJ, Song WC, Lambris JD, Cines DB, Meyer NJ, Mangalmurti NS (2020) Erythrocytes reveal complement activation in patients with COVID-19. medRxiv. https:\/\/doi.org\/10.1101\/2020.05.20.20104398","journal-title":"medRxiv"},{"key":"704_CR20","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.260117","author":"R Peffault de Latour","year":"2020","unstructured":"Peffault de Latour R, Bergeron A, Lengline E, Dupont T, Marchal A, Galicier L, de Castro N, Bondeelle L, Darmon M, Dupin C, Dumas G, Leguen P, Madelaine I, Chevret S, Molina JM, Azoulay E, Fremeaux-Bacchi V, Core G (2020) Complement C5 inhibition in patients with COVID-19\u2014a promising target? Haematologica. https:\/\/doi.org\/10.3324\/haematol.2020.260117","journal-title":"Haematologica"},{"issue":"1","key":"704_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jaci.2020.05.006","volume":"146","author":"M Cugno","year":"2020","unstructured":"Cugno M, Meroni PL, Gualtierotti R, Griffini S, Grovetti E, Torri A, Panigada M, Aliberti S, Blasi F, Tedesco F, Peyvandi F (2020) Complement activation in patients with COVID-19: a novel therapeutic target. J Allergy Clin Immunol 146(1):215\u2013217. https:\/\/doi.org\/10.1016\/j.jaci.2020.05.006","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"704_CR22","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/s41577-020-0314-5","volume":"20","author":"CM Wilk","year":"2020","unstructured":"Wilk CM (2020) Coronaviruses hijack the complement system. Nat Rev Immunol 20(6):350. https:\/\/doi.org\/10.1038\/s41577-020-0314-5","journal-title":"Nat Rev Immunol"},{"key":"704_CR23","doi-asserted-by":"crossref","unstructured":"Gao T, Hu MD, Zhang XP, Li HZ (2020) Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. medRxiv:2020.2003.2029.20041962","DOI":"10.1101\/2020.03.29.20041962"},{"key":"704_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2020.04.007","volume":"220","author":"C Magro","year":"2020","unstructured":"Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, Baxter-Stoltzfus A, Laurence J (2020) Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 220:1\u201313","journal-title":"Transl Res"},{"issue":"40","key":"704_CR25","doi-asserted-by":"publisher","first-page":"25018","DOI":"10.1073\/pnas.2010540117","volume":"117","author":"JC Holter","year":"2020","unstructured":"Holter JC, Pischke SE, de Boer E, Lind A, Jenum S, Holten AR, Tonby K, Barratt-Due A, Sokolova M, Schjalm C, Chaban V, Kolderup A, Tran T, Tollefsrud Gjlberg T, Skeie LG, Hesstvedt L, Ormsen V, Fevang B, Austad C, Muller KE, Fladeby C, Holberg-Petersen M, Halvorsen B, Muller F, Aukrust P, Dudman S, Ueland T, Andersen JT, Lund-Johansen F, Heggelund L, Dyrhol-Riise AM, Mollnes TE (2020) Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patien ts. Proc Natl Acad Sci U S A 117(40):25018\u201325025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"704_CR26","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-33390\/v1","author":"B Yan","year":"2020","unstructured":"Yan B, Freiwald T, Chauss D, Wang L, West E, Bibby J, Olson M, Kordasti S, Portilla D, Laurence A, Lionakis MS, Kemper C, Afzali B, Kazemian M (2020) SARS-CoV2 drives JAK1\/2-dependent local and systemic complement hyper-activation. Res Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-33390\/v1","journal-title":"Res Sq"},{"issue":"1","key":"704_CR27","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.kint.2020.04.003","volume":"98","author":"H Su","year":"2020","unstructured":"Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, Yi F, Yang HC, Fogo AB, Nie X, Zhang C (2020) Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int 98(1):219\u2013227. https:\/\/doi.org\/10.1016\/j.kint.2020.04.003","journal-title":"Kidney Int"},{"issue":"2","key":"704_CR28","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.kint.2020.05.013","volume":"98","author":"M Noris","year":"2020","unstructured":"Noris M, Benigni A, Remuzzi G (2020) The case of complement activation in COVID-19 multiorgan impact. Kidney Int 98(2):314\u2013322. https:\/\/doi.org\/10.1016\/j.kint.2020.05.013","journal-title":"Kidney Int"},{"issue":"6","key":"704_CR29","doi-asserted-by":"publisher","first-page":"F1454","DOI":"10.1152\/ajprenal.00160.2020","volume":"318","author":"MA Martinez-Rojas","year":"2020","unstructured":"Martinez-Rojas MA, Vega-Vega O, Bobadilla NA (2020) Is the kidney a target of SARS-CoV-2? Am J Physiol Ren Physiol 318(6):F1454\u2013F1462. https:\/\/doi.org\/10.1152\/ajprenal.00160.2020","journal-title":"Am J Physiol Ren Physiol"},{"key":"704_CR30","doi-asserted-by":"publisher","unstructured":"Diao B, Wang C, Wang R, Feng Z, Tan Y, Wang H, Wang C, Liu L, Liu Y, Liu Y, Wang G, Yuan Z, Ren L, Wu Y, Chen Y (2020) Human kidney is a target for novel severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection. medRxiv:2020.2003.2004.20031120. https:\/\/doi.org\/10.1101\/2020.03.04.20031120","DOI":"10.1101\/2020.03.04.20031120"},{"key":"704_CR31","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-1711","author":"F Licciardi","year":"2020","unstructured":"Licciardi F, Pruccoli G, Denina M, Parodi E, Taglietto M, Rosati S, Montin D (2020) SARS-CoV-2-induced Kawasaki-like hyperinflammatory syndrome: a novel COVID phenotype in children. Pediatrics. https:\/\/doi.org\/10.1542\/peds.2020-1711","journal-title":"Pediatrics"},{"key":"704_CR32","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01753-18","author":"LE Gralinski","year":"2018","unstructured":"Gralinski LE, Sheahan TP, Morrison TE, Menachery VD, Jensen K, Leist SR, Whitmore A, Heise MT, Baric RS (2018) Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. MBio. https:\/\/doi.org\/10.1128\/mBio.01753-18","journal-title":"MBio"},{"issue":"1","key":"704_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41426-018-0063-8","volume":"7","author":"Y Jiang","year":"2018","unstructured":"Jiang Y, Zhao G, Song N, Li P, Chen Y, Guo Y, Li J, Du L, Jiang S, Guo R, Sun S, Zhou Y (2018) Blockade of the C5a\u2013C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect 7(1):77. https:\/\/doi.org\/10.1038\/s41426-018-0063-8","journal-title":"Emerg Microbes Infect"},{"issue":"6","key":"704_CR34","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41577-020-0320-7","volume":"20","author":"AM Risitano","year":"2020","unstructured":"Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F, Lambris JD (2020) Complement as a target in COVID-19? Nat Rev Immunol 20(6):343\u2013344","journal-title":"Nat Rev Immunol"},{"key":"704_CR35","doi-asserted-by":"publisher","first-page":"108450","DOI":"10.1016\/j.clim.2020.108450","volume":"215","author":"S Mastaglio","year":"2020","unstructured":"Mastaglio S, Ruggeri A, Risitano AM, Angelillo P, Yancopoulou D, Mastellos DC, Huber-Lang M, Piemontese S, Assanelli A, Garlanda C, Lambris JD, Ciceri F (2020) The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol 215:108450. https:\/\/doi.org\/10.1016\/j.clim.2020.108450","journal-title":"Clin Immunol"},{"key":"704_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15187","author":"S Jodele","year":"2020","unstructured":"Jodele S, Kohl J (2020) Tackling COVID-19 infection through complement-targeted immunotherapy. Br J Pharmacol. https:\/\/doi.org\/10.1111\/bph.15187","journal-title":"Br J Pharmacol"},{"issue":"8","key":"704_CR37","doi-asserted-by":"publisher","first-page":"e12642","DOI":"10.15252\/emmm.202012642","volume":"12","author":"A Polycarpou","year":"2020","unstructured":"Polycarpou A, Howard M, Farrar CA, Greenlaw R, Fanelli G, Wallis R, Klavinskis LS, Sacks S (2020) Rationale for targeting complement in COVID-19. EMBO Mol Med 12(8):e12642. https:\/\/doi.org\/10.15252\/emmm.202012642","journal-title":"EMBO Mol Med"},{"issue":"12","key":"704_CR38","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa061648","volume":"355","author":"P Hillmen","year":"2006","unstructured":"Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, Roth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355(12):1233\u20131243. https:\/\/doi.org\/10.1056\/NEJMoa061648","journal-title":"N Engl J Med"},{"issue":"1","key":"704_CR39","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","volume":"68","author":"F Fakhouri","year":"2016","unstructured":"Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provot F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM (2016) Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, Open-Label Trial. Am J Kidney Dis 68(1):84\u201393. https:\/\/doi.org\/10.1053\/j.ajkd.2015.12.034","journal-title":"Am J Kidney Dis"},{"issue":"23","key":"704_CR40","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nurnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368(23):2169\u20132181. https:\/\/doi.org\/10.1056\/NEJMoa1208981","journal-title":"N Engl J Med"},{"issue":"13","key":"704_CR41","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1182\/blood.2019004218","volume":"135","author":"S Jodele","year":"2020","unstructured":"Jodele S, Dandoy CE, Lane A, Laskin BL, Teusink-Cross A, Myers KC, Wallace G, Nelson A, Bleesing J, Chima RS, Hirsch R, Ryan TD, Benoit S, Mizuno K, Warren M, Davies SM (2020) Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood 135(13):1049\u20131057. https:\/\/doi.org\/10.1182\/blood.2019004218","journal-title":"Blood"},{"key":"704_CR42","doi-asserted-by":"publisher","first-page":"175628642093203","DOI":"10.1177\/1756286420932035","volume":"13","author":"V Velez-Santamaria","year":"2020","unstructured":"Velez-Santamaria V, Nedkova V, Diez L, Homedes C, Alberti MA, Casasnovas C (2020) Eculizumab as a promising treatment in thymoma-associated myasthenia gravis. Ther Adv Neurol Disord 13:1756286420932035. https:\/\/doi.org\/10.1177\/1756286420932035","journal-title":"Ther Adv Neurol Disord"},{"issue":"7","key":"704_CR43","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.26355\/eurrev_202004_20875","volume":"24","author":"F Diurno","year":"2020","unstructured":"Diurno F, Numis FG, Porta G, Cirillo F, Maddaluno S, Ragozzino A, De Negri P, Di Gennaro C, Pagano A, Allegorico E, Bressy L, Bosso G, Ferrara A, Serra C, Montisci A, D\u2019Amico M, Schiano Lo Morello S, Di Costanzo G, Tucci AG, Marchetti P, Di Vincenzo U, Sorrentino I, Casciotta A, Fusco M, Buonerba C, Berretta M, Ceccarelli M, Nunnari G, Diessa Y, Cicala S, Facchini G (2020) Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci 24(7):4040\u20134047. https:\/\/doi.org\/10.26355\/eurrev_202004_20875","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"704_CR44","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1186\/s13063-020-04548-z","volume":"21","author":"K Smith","year":"2020","unstructured":"Smith K, Pace A, Ortiz S, Kazani S, Rottinghaus S (2020) A Phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of intravenously administered ravulizumab compared with best supportive care in patients with COVID-19 severe pneumonia, acute lung injury, or acute respiratory distress syndrome: a structured summary of a study protocol for a randomised controlled trial. Trials 21(1):639. https:\/\/doi.org\/10.1186\/s13063-020-04548-z","journal-title":"Trials"},{"issue":"18","key":"704_CR45","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1182\/blood.2020008248","volume":"136","author":"J Yu","year":"2020","unstructured":"Yu J, Yuan X, Chen H, Chaturvedi S, Braunstein EM, Brodsky RA (2020) Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood 136(18):2080\u20132089. https:\/\/doi.org\/10.1182\/blood.2020008248","journal-title":"Blood"},{"issue":"8","key":"704_CR46","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1182\/blood-2016-08-732800","volume":"129","author":"MJ Harder","year":"2017","unstructured":"Harder MJ, Kuhn N, Schrezenmeier H, H\u00f6chsmann B, von Zabern I, Weinstock C, Simmet T, Ricklin D, Lambris JD, Skerra A, Anliker M, Schmidt CQ (2017) Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. Blood 129(8):970\u2013980. https:\/\/doi.org\/10.1182\/blood-2016-08-732800","journal-title":"Blood"},{"key":"704_CR47","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.236877","author":"RA Brodsky","year":"2020","unstructured":"Brodsky RA, Peffault de Latour R, Rottinghaus ST, R\u00f6th A, Risitano AM, Weitz IC, Hillmen P, Maciejewski JP, Szer J, Lee JW, Kulasekararaj AG, Volles L, Damokosh AI, Ortiz S, Shafner L, Liu P, Hill A, Schrezenmeier H (2020) Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2019.236877","journal-title":"Haematologica"},{"key":"704_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2600-6","author":"J Carvelli","year":"2020","unstructured":"Carvelli J, Demaria O, Vely F, Batista L, Benmansour NC, Fares J, Carpentier S, Thibult ML, Morel A, Remark R, Andre P, Represa A, Piperoglou C, Explore C-IPHg, Explore C-MIg, Cordier PY, Le Dault E, Guervilly C, Simeone P, Gainnier M, Morel Y, Ebbo M, Schleinitz N, Vivier E (2020) Association of COVID-19 inflammation with activation of the C5a\u2013C5aR1 axis. Nature. https:\/\/doi.org\/10.1038\/s41586-020-2600-6","journal-title":"Nature"},{"issue":"9","key":"704_CR49","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41573-019-0031-6","volume":"18","author":"DC Mastellos","year":"2019","unstructured":"Mastellos DC, Ricklin D, Lambris JD (2019) Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov 18(9):707\u2013729. https:\/\/doi.org\/10.1038\/s41573-019-0031-6","journal-title":"Nat Rev Drug Discov"},{"key":"704_CR50","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/cei.13497","volume":"203","author":"S Elhadad","year":"2020","unstructured":"Elhadad S, Chapin J, Copertino D, Van Besien K, Ahamed J, Laurence J (2020) MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab. Clin Exp Immunol 203:96\u2013104","journal-title":"Clin Exp Immunol"},{"key":"704_CR51","doi-asserted-by":"publisher","first-page":"152001","DOI":"10.1016\/j.imbio.2020.152001","volume":"225","author":"A Rambaldi","year":"2020","unstructured":"Rambaldi A, Gritti G, Mic MC, Frigeni M, Borleri G, Salvi A, Landi F, Pavoni C, Sonzogni A, Gianatti A, Binda F, Fagiuoli S, Di Marco F, Lorini L, Remuzzi G, Whitaker S, Demopulos G (2020) Endothelial injury and thrombotic microangiopathy in COVID-19: treatment with the lectin-pathway inhibitor narsoplimab. Immunobiology 225:152001","journal-title":"Immunobiology"}],"container-title":["Medical Microbiology and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00430-021-00704-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00430-021-00704-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00430-021-00704-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T18:04:14Z","timestamp":1621533854000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00430-021-00704-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,3]]},"references-count":51,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["704"],"URL":"https:\/\/doi.org\/10.1007\/s00430-021-00704-7","relation":{},"ISSN":["0300-8584","1432-1831"],"issn-type":[{"value":"0300-8584","type":"print"},{"value":"1432-1831","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,3]]},"assertion":[{"value":"4 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}